Period of time： 2013年2期
Publisher： Future Medicine
Founded in： 2005
Total resources： 43
ISSN： 1479-6678
Subject： R5 Internal Medicine
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Future Cardiology,volume 1,issue 2
Menu
Future strategies in the management of dyslipidemia
By Birjmohun Rakesh S,Stroes Erik SG,Kastelein John JP in (2005)
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.
Access to resources
Recommend
A review of the pharmacokinetics, electrophysiology and clinical efficacy of dronedarone
By Hynes B John,Luck Jerry C,Wolbrette Deborah L,Khan Mazhar,Naccarelli Gerald V in (2005)
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.Current and future uses of nesiritide
By Hobbs Robert E,Tang Wilson in (2005)
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.8th Annual NewEra Cardiac Care: Innovation & technology
By Reade Clifton C,Kypson Alan P P,Chitwood W Randolph in (2005)
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.Cardioprotective anesthesia in patients undergoing coronary surgery: fact or fiction?
By Lehmann Andreas,Boldt Joachim,Isgro Frank in (2005)
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.Current status of myocardial regeneration and cell transplantation
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.Targets for immunomodulation in cardiovascular disease – where are we now?
By Wainwright Cherry L in (2005)
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.The glycoprotein IIIa gene polymorphism and the risk of myocardial infarction
Future Cardiology,volume 1,issue 2 , Vol. 1, Iss. 2, 2005-03 , pp.
Previous
Next